EP1802296A1 - Compositions pour le soin de la peau comprenant l'amide nicotinique et un absorbent - Google Patents

Compositions pour le soin de la peau comprenant l'amide nicotinique et un absorbent

Info

Publication number
EP1802296A1
EP1802296A1 EP05796527A EP05796527A EP1802296A1 EP 1802296 A1 EP1802296 A1 EP 1802296A1 EP 05796527 A EP05796527 A EP 05796527A EP 05796527 A EP05796527 A EP 05796527A EP 1802296 A1 EP1802296 A1 EP 1802296A1
Authority
EP
European Patent Office
Prior art keywords
composition
composition according
nicotinamid
skin
urease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05796527A
Other languages
German (de)
English (en)
Inventor
Francoise Deperraz
Susanne Gosdschan-Amann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Priority to EP05796527A priority Critical patent/EP1802296A1/fr
Publication of EP1802296A1 publication Critical patent/EP1802296A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • Acidic and buffered skin-care compositions comprising nicotinamid and an absorbing agent
  • the invention relates to skin-care compositions comprising nicotinamid and an absorbing agent.
  • the invention relates also to medicaments comprising said compositions, being advantageously used for treating and/or preventing minor to moderate skin irritations.
  • diaper dermatits which in its most commun form represents an irritant contact dermatitis.
  • the diapered skin of attorneys is frequently exposed to a warm, moist atomic structure, and increased hydratation of skin is known to cause increased friction and abrasion, increases permeability and elevated microbial counts.
  • ammonia is implicated in the genesis of diaper dermatitis. More recently, it has been reported that ammonia may play an indirect role, involving an interaction between urine and feces.
  • the direct effect on skin can be attributed to fecal enzymes, particularly proteases and lipases, that become more active and thus more damaging as the pH increases.
  • the pH increase is the result of ammonia production from urinary urea through the action of fecal urease.
  • Urine and feces are commonly present in the diaper at the same time, and exposure of the skin to these materials for several hours is not uncommon, particularly in the overnight diaper, providing suitable conditions and ample time for this interaction and resulting skin damage to occur.
  • lipases and proteases are skin irritants that may be involved in the induction of diaper dermatitis (Etiologic factors inndiaper dermatitis: the role of urine, Ronald W. Berg et al, Pediatric Dermatology, Vol. 3 No 2. 102-106).
  • urine may also contain materials that irritate skin directly, particularly after prolonged exposure.
  • rashes are, generally, caused by allergies, exposures of the skin to periods of cold weather, or exposure to hot, humid conditions, such as washing dishes or the like, or exposure to irritating materials in topical products or ingredients (e. g., retinoiod, hydroxy acids, keto acids). These rashes can also be caused by excessive dryness of the skin without adequate skin moisturization.
  • compositions intented for the treatment of minor skin irritations, containing a safe and effective amount of natural or synthetic vitamin B3 compounds as an anti-irritant agent.
  • the compositions comprise as essential components a vitamin B3 component and a dermatologically acceptable carrier.
  • the compositions may comprise optional components but the disclosed compositions do not comprise an absorbing agent.
  • the compositions have a pH of from about 4 to about 7.
  • the patent application WO99/63982 discloses a method for treating diaper dermatitis in a human which comprises the steps of:
  • the invention relates to an acidic and buffered composition
  • an acidic and buffered composition comprising:
  • composition means that said composition has a pH value which is lower than 7.
  • a buffered composition is formulated to provide a capacity of resistance to an increase of pH induced by the addition of an alkaline agent.
  • the composition may be buffered by the addition of buffering agents which include but are not limited to citrates (disodium citrate/trisodium citrate) or phosphates (potassium dihydrogen phosphate and disodium hydrogen phosphate).
  • buffering agents include but are not limited to citrates (disodium citrate/trisodium citrate) or phosphates (potassium dihydrogen phosphate and disodium hydrogen phosphate).
  • Preverence is given to a buffered composition comprising disodium citrate, trisodium citrate potassium dihydro ⁇ gen phosphate, disodium hydrogen phosphate or mixtures thereof.
  • the buffer capacity can be quantified by the volume of alkaline solution added to reach a fixed pH.
  • the composition has advantageously a pH value in the range of 4 to 7, more advantageously from 4.4 to 6.0, even more advantageously from 5.0 to 6.0.
  • Nicotinamid is a vitamin B 3 compound having the following formula:
  • Salts of the vitamin B 3 compound are also useful herein.
  • Nonlimiting examples of salts of the vitamin B 3 compound useful herein include organic or inorganic salts, such as inorganic salts with anionic inorganic species (e. g., chloride, bromide, iodide, carbonate), and organic carboxylic acid salts (including mono-, di-and tri-Ci-Cis carboxylic acid salts, e. g., acetate, salicylate, glycolate, lactate, malate, citrate).
  • anionic inorganic species e. g., chloride, bromide, iodide, carbonate
  • organic carboxylic acid salts including mono-, di-and tri-Ci-Cis carboxylic acid salts, e. g., acetate, salicylate, glycolate, lactate, malate, citrate.
  • absorbing agents are finely powdered materials incorporated in high concentration in semi-solid preparations (pastes) inducing absorptive characteristics to the preparations.
  • Several methods are described in the litterature to quantify their absorptive feature by measuring the quantity of water absorbed either after incubation or through water permeable film (Juch; Rufi; Surber; in Dermatology 1994; 189 :373-377 and Rae in Brit. J. Dermat. 1947;59,338- 39).
  • Absorbing agents according to the invention include but are not limited to zinc oxide, titanium dioxide, starch, talc, kaolin, aluminium stearate, magnesium carbonate or a mixture thereof which are the most commonly used absorbing agents.
  • Preverence is given to a composition comprising talc, titanium dioxide, titanium dioxide treated with a silicone derivative or fatty acids, zinc oxide treated with a silicone derivative or fatty acids or mixtures thereof.
  • the silicon derivative is advantageously selected from the group consisting of methicone, dimethicone and cyclopenta- siloxane.
  • the absorbing agent is titanium dioxide treated with fatty acids or zinc oxide treated with fatty acids, the fatty acids are advantageously selected from the group consisting of stearic acid, mystiric acid and mixtures thereof.
  • the absorbing agent is titanium dioxide.
  • titanium dioxide is used in anatase crystalline form with an average primary crystal size ranging from 0.2 to 0.4 ⁇ m.
  • the composition comprises 5 % to 20 %, by weight of the composition, of one of said absorbing agents, advandageously 5 % to 15 % by weight of the composition, of one of said absorbing agents. If a mixture of absorbing agents is used the total amount of the absorbing agents in the composition is 5 % to 40 %, preferably 10 % to 30 %, more preferably 15% to 25 % by weight of the composition.
  • the composition advantageously comprises 0.1 % to 4 %, preferably 0.3 to 2.5 %, by weight of the composition, of nicotinamid.
  • the composition may further comprise physiological skin lipids which include but are not limited to ceramide, cholesterol, palmitic acid and linoleic acid; other vitamins, in particular specific vitamins to help healing process which include but are not limited to dexpanthenol and vitamin E; anti-pruritic agents which include but are not limited to glycine; moisturising agents which include but are not limited to glycerin, sorbitol and xylitol.
  • the composition comprises dexpanthenol and vitamin E.
  • the composition comprises dexpanthenol in an amount of 3 % to 10 %, preferably 4 % to 8 % by weight of the composition.
  • composition may further comprise a vitamin C compound in combination with or instead of nicotinamid.
  • the composition does not comprise ethanol or preservatives; the composition is preservative and ethanol free.
  • the composition may comprise a synthetic or a natural emulsifier which include but are not limited to cetearylglucoside, cocoylglucoside, bis-PEG/PPG-16/16 PEG/PPG-16/16 dimethicone, tribehenin
  • PEG-20 esters glyceryl stearate, PEG-75 stearate, ceteth-20, Ceteareth-12, ceteareth-20, steareth- 20, poly glycery 1-3 -diisostearate, polyglyceryl-2-dihydroxystearate, PEG-30 dipolyhydroxy- stearate, cetyl PEG/PPG-10/1 dimethicone, bis PEG/PPG-14/14 dimethicone.
  • composition of the present invention may also be included in the composition of the present invention which include but are not limited to iscosifying agents and emulsion stabilizers like xanthan gum, cetearyl alcohol, PVP, PEG-75, sodium alginate, carbomer, guar gum, emollients like caprilic/capric triglycerides, squalane, dimethicone, water resistant and film former agents like PVP eicosene Copolymer, C20-22 alkyl phosphate/C20-22 alcohols, colorants like iron oxides.
  • iscosifying agents and emulsion stabilizers like xanthan gum, cetearyl alcohol, PVP, PEG-75, sodium alginate, carbomer, guar gum, emollients like caprilic/capric triglycerides, squalane, dimethicone, water resistant and film former agents like PVP eicosene Copolymer, C20-22 alkyl phosphat
  • composition complies with the EP standards for efficacy of antimicrobial preservation, what means that after inoculation of 10 5 to 10 6 micro-organisms the log reduction must be the following :
  • composition of the present invention also contains a dermatologically acceptable carrier.
  • dermatologically acceptable carrier means that the carrier is suitable for topical application to the skin, has good aesthetic properties, is compatible with the actives of the present invention and any other components, and will not cause any untoward safety or toxicity concerns.
  • a safe and effective amount of carrier is from about 40% to about 90%, preferably from about 45% to about 85%, more preferably from about 50% to about 80% by weight of the composition.
  • the carrier can be in a wide variety of forms.
  • emulsion carriers including, but not limited to, oil-in-water (e.g. emulgel), water-in-oil, water-in-oil-in-water, and oil-in-water- in-silicone emulsions, are useful herein.
  • Preferred cosmetically and/or pharmaceutically acceptable topical carriers include oil-in-water emulsions.
  • emulsions can also be delivered in the form of sprays using either mechanical pump containers or pressurized aerosol containers using conventional propellants.
  • These carriers can also be delivered in the form of a mousse.
  • suitable topical carriers include anhydrous liquid solvents such as oils, and silicones; aqueous-based single phase liquid solvents; and thickened versions of these anhydrous and aqueous-based single phase solvents.
  • the composition of the present invention is generally prepared by conventional methods such as are known in the art of making topical compositions.
  • Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • the product form can be a cream, paste, gel, emulsion, lotion, ointment, solution, liquid, mousse, foam etc.
  • composition is useful for treating or preventing minor skin eruptions, redness, itchiness, dryness, rashes, and chapping in mammals, especially humans.
  • composition is advantageously topically applied to the skin.
  • the invention also relates to a medicament comprising a composition as described above.
  • the medicament is useful for treating or preventing the irritation of mammalian skin.
  • the medicament is useful for treating or preventing skin eruptions, itchiness, rashes, and chapping in mammals, especially humans.
  • the medicament is particularly intented for the treatment and/pr the prevention of diaper dermatitis.
  • the medicament is advantageously topically applied to the skin.
  • the medicament may be in the form of a cream, paste, skin lotion, gel or the like which is intended to be left on the skin.
  • the amount of the medicament which is applied, the frequency of application and the period of use will vary widely depending upon the level of irritation reduction desired.
  • the invention further relates to the use of the above-described composition as an anti- urease agent, ie the above-described composition may be used for inhibit the urease activity.
  • Example 1 formulae comprising Nicotinamid according to the present invention
  • Example 2 Buffer capacity of the compositions according to the invention
  • the buffer capacity can be quantified by the volume of alkaline solution added to reach a fixed pH.
  • Protocol Test is done by titrimetry
  • Table 8 Proposed specification more than 3.0 ml, preferably more than 4.5 ml of ammonia 0.1M to reach pH 8.
  • compositions according to the invention could be called buffered compositions.
  • the purpose of this example is to test the inhibitory effect of some molecules on the activity of urease. Suitable conditions (T°, time, concentration) for which urease produces amounts of measurable ammonia were determined. In the same conditions, increasing concentrations of nicotinamid are added.
  • Enzyme activity is determined by incubation of the sample with urease and subsequent determination of released ammonia using an indophenol reaction along with parallel standardi ⁇ sation with ammonia.
  • Suitable urease and ammonia concentrations were determined by preliminary tests to get a linear signal (between 0 and 1.2 O.D. at 630 nm) after 30' of colorimetric reaction.
  • microplate was incubated for 15' at room temperature after urease addition (enzymatic reaction) and then incubated for 30' after addition of reagent A and reagent B (60 ⁇ L and 90 ⁇ L respectively » indophenol colorimetric reaction).
  • blank is the sum of urease blank and sample blank.
  • blank is the standard blank.
  • Example 4 Inhibition of the Jack Bean UREASE activity by the compositions according to the invention The purpose of this example is to compare the inhibition of urease activity by a cream placebo and a cream containing 0.5%, 1%, 2% nicotinamid.
  • formulae 5B, 5C, 5E and formula 5E' which is the same as formula 5E provided that it comprises 47.5 % w/w water instead of 47 % w/w and 0% w/w nicotinamid instead of 0.5 % w/w, have been tested.
  • Reagent A phenol 6 g/100 ml sodium nitroprusside 25 mg/100 ml ad "Buffer pH 12" to complete volume
  • Reagent B NaOH 16 g/1
  • composition Sample with 2%, 1%, 0.5%, 0% nicotinamid
  • test tube contained 250 ⁇ l urea 4 %
  • Each tube was incubated 15' at room temperature with urease.
  • the tubes were centrifugated 15' 10000 RPM.
  • cream dilutions The two major consequences of the cream dilutions are a lower matrix effect and a reduction of the nicotinamid concentration.
  • This inhibitory effect of nicotinamid was shown by comparison of results obtained for the placebo and the sample.
  • the optimal dilution will be chosen for its best ratio between placebo and sample inhibitory effect.
  • 200, 400, 600 and 800 fold dilutions of cream - nicotinamid 2% were tested.
  • 100, 200 and 300 fold dilutions were tested for the cream - nicotinamid 0.5%.
  • duplicates were prepared and tested in quadruplicate. Average and RSD were calculated for each series (8 results).

Abstract

La présente invention a trait à des compositions de soins cutanés acides et tamponnées comportant du nicotinamide et un agent absorbant, choisi parmi du dioxyde de titane, du dioxyde traité avec un dérivé de silicone ou des acides gras, de l'oxyde de zinc traité avec un dérivé de silicone ou des acides gras ou des mélanges de ceux-ci. L'invention a également trait à des médicaments comprenant lesdites compositions utilisés pour le traitement et/ou la prévention d'irritations cutanées mineures, notamment la dermatite. L'invention a trait enfin aux dites compositions en tant qu'agents anti-uréase.
EP05796527A 2004-10-15 2005-10-05 Compositions pour le soin de la peau comprenant l'amide nicotinique et un absorbent Withdrawn EP1802296A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05796527A EP1802296A1 (fr) 2004-10-15 2005-10-05 Compositions pour le soin de la peau comprenant l'amide nicotinique et un absorbent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292455 2004-10-15
EP05796527A EP1802296A1 (fr) 2004-10-15 2005-10-05 Compositions pour le soin de la peau comprenant l'amide nicotinique et un absorbent
PCT/EP2005/010701 WO2006040048A1 (fr) 2004-10-15 2005-10-05 Compositions de soins cutanes acides et tamponnees comportant du nicotinamide et un agent absorbant

Publications (1)

Publication Number Publication Date
EP1802296A1 true EP1802296A1 (fr) 2007-07-04

Family

ID=34931458

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05796527A Withdrawn EP1802296A1 (fr) 2004-10-15 2005-10-05 Compositions pour le soin de la peau comprenant l'amide nicotinique et un absorbent

Country Status (8)

Country Link
EP (1) EP1802296A1 (fr)
AR (1) AR053978A1 (fr)
AU (1) AU2005293830B2 (fr)
BR (1) BRPI0518160A (fr)
MX (1) MX2007004280A (fr)
RU (1) RU2401100C2 (fr)
TW (1) TW200626135A (fr)
WO (1) WO2006040048A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2741656T3 (es) * 2012-12-14 2020-02-11 Unilever Nv Niacinamida para inducir la generación de péptidos antimicrobianos
CN113908074A (zh) * 2014-05-12 2022-01-11 联合利华知识产权控股有限公司 用于诱导抗微生物肽生成的烟酰胺
FR3066194B1 (fr) * 2017-05-12 2020-01-31 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Procede de synthese d'aminoacides n-acyles sans utiliser de solvants ni de chlorure d'acide
CN110785161B (zh) 2017-06-23 2023-06-20 宝洁公司 用于改善皮肤外观的组合物和方法
US10874600B2 (en) 2018-06-18 2020-12-29 The Procter & Gamble Company Method for degrading bilirubin in skin
WO2020010036A1 (fr) 2018-07-03 2020-01-09 The Procter & Gamble Company Méthode de traitement d'une affection cutanée
US11571379B2 (en) 2020-01-24 2023-02-07 The Procter & Gamble Company Skin care composition
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
WO2021247496A1 (fr) 2020-06-01 2021-12-09 The Procter & Gamble Company Méthode d'amélioration de la pénétration d'un composé de vitamine b3 dans la peau

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564307A1 (fr) * 1992-04-03 1993-10-06 Shalom Levi Préparation pour la prévention de l'irritation de la peau
US20040013744A1 (en) * 2002-07-17 2004-01-22 Goulbourne Mary J. Ointment composition for treating decubitus ulcers and methods for its making and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759524A (en) * 1996-02-09 1998-06-02 The Procter & Gamble Company Photoprotective compositions
WO1999047141A1 (fr) * 1998-03-16 1999-09-23 The Procter & Gamble Company Methode de traitement des irritations de la peau
BR9917188A (pt) * 1999-03-03 2002-01-02 Procter & Gamble Composição para cuidado da pele
US6444647B1 (en) * 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
JP2002003378A (ja) * 2000-06-22 2002-01-09 Kanebo Ltd 外用抗掻痒剤
DE10063090A1 (de) * 2000-12-18 2002-06-20 Henkel Kgaa Nanoskaliges ZnO in Hygiene-Produkten
US6936241B2 (en) * 2001-08-17 2005-08-30 The Procter & Gamble Company Sunscreen composition
DE10209110A1 (de) * 2002-03-01 2003-09-11 Beiersdorf Ag Hautschutzstift
US20040167479A1 (en) * 2003-02-20 2004-08-26 The Procter & Gamble Company Hemorrhoid treatment pad

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564307A1 (fr) * 1992-04-03 1993-10-06 Shalom Levi Préparation pour la prévention de l'irritation de la peau
US20040013744A1 (en) * 2002-07-17 2004-01-22 Goulbourne Mary J. Ointment composition for treating decubitus ulcers and methods for its making and its use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006040048A1 *

Also Published As

Publication number Publication date
RU2401100C2 (ru) 2010-10-10
BRPI0518160A (pt) 2008-11-04
MX2007004280A (es) 2007-05-16
AU2005293830B2 (en) 2010-10-21
RU2007117790A (ru) 2008-11-20
WO2006040048A1 (fr) 2006-04-20
TW200626135A (en) 2006-08-01
AU2005293830A1 (en) 2006-04-20
AR053978A1 (es) 2007-05-30

Similar Documents

Publication Publication Date Title
AU2005293830B2 (en) Acidic and buffered skin-care compositions comprising nicotinamid and an absorbing agent
Soni et al. Evaluation of the health aspects of methyl paraben: a review of the published literature
Soni et al. Safety assessment of propyl paraben: a review of the published literature
Soni et al. Safety assessment of esters of p-hydroxybenzoic acid (parabens)
AU757681B2 (en) Preventives/remedies for skin diseases
EP1392282B1 (fr) Compositions dermatologiques et cosmetiques comprenant un dérivé de furfuryle
US5961997A (en) Antipruritic composition
ES2212319T3 (es) Composiciones cosmeticas anti-microbianas.
JP2002506821A (ja) 皮膚刺激の治療方法
US5536502A (en) Skin-tear medicament and method of use
TW201605444A (zh) 包含奧替尼啶二鹽酸鹽之局部醫藥組成物或化妝品組成物
EP2566455B1 (fr) Composition topique et son utilisation pour la prévention et le traitement de défauts liés à des dermopathies inflammatoires
US20180360712A1 (en) Cosmetic composition and use thereof
JP2017502053A (ja) 炎症性皮膚状態を治療するためのアラントイン組成物
US5565189A (en) Wound cleanser method of use
WO1999026613A1 (fr) Compositions a base d'aminoguanidine destinees au traitement de dermatoses proliferantes
US6117904A (en) Treatment of pruritus
US6114389A (en) Use of a pharmaceutically acceptable oxalate derivative for the treatment of skin conditions
WO2018084112A1 (fr) Agent antibactérien sélectif vis-à-vis de la souche responsable de l'acné
NZ205587A (en) Composition comprising undecylenic acid for treating herpes simplex i
JPS6054932B2 (ja) 治療組成物
EA036748B1 (ru) Глюконо--лактон для лечения вагинальных грибковых инфекций
EP1216021B1 (fr) Compositions pharmaceutiques et/ou cosmetiques
CA3110856A1 (fr) Procedes et compositions pour renforcer la croissance des cheveux et/ou prevenir la chute des cheveux
JP2001270828A (ja) 尋常性座瘡予防治療外用剤及びその外用剤を配合した化粧料

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100930